The recent analyst ratings for the stock indicate that the stock may be closing in on the higher end of the expectations. Deutsche Bank increased its price target from $7 to $9 and Zacks recently gave a PT of $10. RBC has increased the target substantially from $8 to $11. Several analysts have a hold or a buy rating on the stock and the average price target is $8.42. The expectations for EPS for 2013 is $0.41, and the forward P/E for 2014 is ~20. This also indicates that the analysts are cautiously optimistic, but further growth in the stock may be a little difficult. This is mainly because the stock has had a good run during the last few months and has doubled from its 52 week low in July. The lower volumes of the stock also indicate that it may be getting a little tired at the top. The good part is that the expectations are for the company to report a net profit in 2013. However, over the years, the company has reported decline in revenues and gross profit. On a net basis also, the company has reported a loss during most of the past years, mainly due to goodwill impairments. The debt on books is also relatively high. The progress on the trials provides positive news from time to time which is the main reason for the cautious optimism. The company has remained in news for results related to trials of its products, and there may be good progress on that front. Innovation is the key to success in this field. Even smaller medical device companies like PLC Systems (PLCSF) are doing well on innovation. PLC Systems has built an IPR portfolio around a single technology it possesses. Bigger companies like Boston Scientific have grown over the years mainly based on innovative technology, and the future also depends on the new products which it may bring to the market.